France Warns 1.6 Million Women on Pill Meningioma Risk

France’s medicines regulator has begun mailing personalized safety letters to roughly 1.6 million women who have taken a desogestrel-based contraceptive pill, warning of a very low but confirmed increase in meningioma risk with prolonged use. The campaign, announced 10 September and reaching patients from 14 September, is the French implementation of an EU-wide label change that Europe’s pharmacovigilance committee ordered in July — and one of the larger direct-to-patient mailings a national medicines agency has run over a single safety signal.

What PRAC found, and what changes on the label

The signal traces back to a December 2024 study from EPI-PHARE, the French public health data group, which first flagged a very low increase in meningioma risk among long-term desogestrel users. Europe’s Pharmacovigilance Risk Assessment Committee (PRAC) took up the finding and, at its 6–9 July 2026 meeting, confirmed it: for desogestrel 75 µg used at least one year, the odds ratio for intracranial meningioma reaches 1.3 (95% CI 1.1–1.5). PRAC recommended EU-wide changes — adding meningioma to the summary of product characteristics and patient leaflet, and introducing a new contraindication for anyone with a current or past meningioma — covering desogestrel and etonogestrel medicines generally, including the Nexplanon implant and combined vaginal rings. A direct healthcare-professional communication went to prescribers across the EU in August.

Why France is writing to patients, not just prescribers

A DHPC to prescribers is the standard EU mechanism for a label change like this one; writing to 1.6 million patients directly is not. ANSM’s decision to do both reflects the scale of exposure and the nature of the risk: it accrues silently over years of continuous use, on a medicine many patients fill on autopilot through a pharmacy refill rather than a fresh conversation with a prescriber. A letter that reaches the patient rather than relying entirely on a pharmacist or physician to relay the update closes that gap — at the cost of running one of the largest single-signal patient mailings a national agency in Europe has attempted.

What patients and prescribers are told to do

• Do not stop the contraceptive without medical advice — the letters and ANSM's guidance are explicit on this point.
• The added risk is higher after age 45 and with prior use of other progestin-containing medicines.
• Meningioma risk falls after the medicine is stopped, resolving roughly a year after discontinuation.
• The new contraindication applies to anyone with a current meningioma or a documented history of one.

For pharmacovigilance and labeling teams elsewhere, the case is a concrete look at EU risk-communication timelines end to end: a December 2024 epidemiological signal, a July 2026 PRAC opinion and label change, an August DHPC to prescribers, and a September direct-to-patient mailing at national scale — nearly two years from first signal to a letter in 1.6 million mailboxes.